Clinical trial · no report yet · Phase 1/Phase 2
NCT05652686
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- NCT05652686 ↗
- Recruiting
- Phanes Therapeutics
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Small Cell Lung Cancer (SCLC); Large Cell Neuroendocrine Cancer (LCNEC); Neuroendocrine Prostate Cancer (NEPC); Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC); Neuroendocrine Carcinomas (NEC); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
- Interventions
- Peluntamig (PT217); Carboplatin + Etoposide; Paclitaxel.; Atezolizumab; Lurbinectedin; Irinotecan (drug); Topotecan
- Arms
- Part A: Dose Escalation · Experimental
- Part B: Dose Expansion · Experimental
- Part C: Chemotherapy Combination Therapy · Experimental
- Part D: ICI Combination Therapy · Experimental
- Enrollment
- 203 (estimated)
- Primary outcomes
- To determine recommended dose for expansion (RDE) of Peluntamig (PT217).
- To evaluate the safety and tolerability of Peluntamig (PT217).
- To evaluate the efficacy of Peluntamig (PT217) monotherapy or in combination treatments as assessed by ORR.
- Sponsor
- Phanes Therapeutics with Hoffmann-La Roche
- Start
- Sep 5, 2023
- Primary completion
- Dec 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05652686 · updated Jul 15, 2026